Health Care • Biotechnology: Pharmaceutical Preparations
$48.64 ▼ -1.86
(-3.68%)
MKT CAP: $1.44B • VOL: 414.4K
52W L $20 52W H $72
ROARABLE / RQD
C- • 60/100
PIOTROSKI
7 / 9
ANAB // SEC EDGAR XBRL STANDARDIZED FINANCIAL STATEMENTS (FA <GO>)
| LINE ITEM (USD / %) | FY 2025
FILED 2025-12-31 | FY 2024
FILED 2024-12-31 | FY 2023
FILED 2023-12-31 |
|---|---|---|---|
| Revenue (Total Sales) | $234.6M | $91.3M | $17.2M |
| YoY Revenue Growth % | +157.0% | +432.0% | — |
| Gross Profit | — | — | — |
| Gross Margin % | — | — | — |
| Research & Development (R&D) | — | — | — |
| Operating Income (EBIT) | $226.9M | $66.2M | -$164.4M |
| Operating Margin % | 85.0% | 72.5% | -80.0% |
| Net Income (GAAP) | -$13.2M | -$145.2M | -$163.6M |
| EBITDA (Normalized) | $227.0M | $66.4M | — |
| Diluted EPS ($/sh) | — | — | — |
| Operating Cash Flow (OCF) | $19.7M | -$135.3M | -$120.8M |
| Capital Expenditures (CapEx) | $87.0K | $358.0K | — |
| Free Cash Flow (FCF) | $19.6M | -$135.7M | -$120.8M |
| FCF Margin % | 8.4% | -80.0% | -80.0% |
| Return on Invested Capital (ROIC %) | 95.0% | 95.0% | — |
| Cash & Short-Term Equivalents | $138.2M | $23.1M | — |
| Total Debt (Short + Long Term) | — | — | — |
| Total Stockholders' Equity | $37.2M | $70.9M | — |
NO QUARTERLY 10-Q XBRL STATEMENTS AVAILABLE IN CURRENT CACHE FOR ANAB.